Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma

Anna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, Mats Jerkeman, Anna Porwit, Daniel Molin, Gunilla Enblad, Arne Kolstad, Riikka Katariina Räty, Martin Hutchings, Caroline E Weibull, Peter Hollander, Sara Ek, Ingrid Glimelius*

*Corresponding author af dette arbejde

Abstract

The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.

OriginalsprogEngelsk
TidsskriftBlood advances
Vol/bind7
Udgave nummer18
Sider (fra-til)5304-5313
Antal sider10
ISSN2473-9529
DOI
StatusUdgivet - 26 sep. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma'. Sammen danner de et unikt fingeraftryk.

Citationsformater